Clinical Report: Embracing Interventional Management in Glaucoma Care

Overview

Traditional glaucoma management relies heavily on patient adherence to topical medications, which often leads to challenges in preventing disease progression. Interventional glaucoma (IG) management offers a proactive approach using early diagnostics, advanced monitoring, and earlier use of laser and surgical interventions to improve long-term outcomes.

Background

Glaucoma has historically been managed reactively, starting with topical anti-glaucoma medications and escalating to laser or surgical interventions only after disease progression. Patient non-adherence to daily eye drops is a significant barrier to effective intraocular pressure (IOP) control. Interventional glaucoma management integrates early diagnostic tools and proactive treatments such as selective laser trabeculoplasty (SLT), sustained-release drug delivery, and minimally invasive glaucoma surgery (MIGS) to reduce reliance on patient compliance. This approach aligns with broader healthcare trends favoring earlier, more aggressive interventions to preserve vision and quality of life.

Data Highlights

Selective laser trabeculoplasty (SLT) improves aqueous outflow by targeting the trabecular meshwork, reducing the need for medications. Sustained-release drug delivery platforms provide medication over months or years, enhancing adherence. MIGS, performed during cataract surgery or as a stand-alone procedure, significantly increase the likelihood of long-term visual stability.

Key Findings

• Traditional glaucoma management is reactive and heavily dependent on patient adherence to topical medications.
• Non-adherence to glaucoma medications is common due to forgetfulness, difficulty with drop instillation, side effects, and systemic concerns.
• Interventional glaucoma management incorporates early diagnostics, advanced monitoring, and proactive interventions such as SLT, sustained-release drug delivery, and MIGS.
• SLT improves aqueous outflow by targeting the trabecular meshwork, reducing medication burden.
• Sustained-release drug delivery platforms provide long-term medication delivery, mitigating adherence issues.
• MIGS enhances long-term visual stability and can be performed during cataract surgery or independently.

Clinical Implications

Adopting interventional glaucoma management allows clinicians to reduce dependence on patient adherence to daily medications by utilizing early and proactive interventions. Integrating these strategies into clinical practice can improve long-term intraocular pressure control and visual outcomes, ultimately enhancing patient quality of life.

Conclusion

Interventional glaucoma management represents a paradigm shift from reactive to proactive care, emphasizing early intervention to preserve vision. Eye care providers are encouraged to embrace this evolving model to lead advancements in glaucoma treatment.

References

1. Mike Cymbor, OD, FAAO -- Glaucoma: Embracing Interventional Management